DR. KIT SANG LAM, M.D., PH.D.
Osteopathic Medicine at X St, Sacramento, CA
License number
California G085338
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
2
4501 X St, Sacramento, CA 95817
1524 Arena Dr, Davis, CA 95616
1524 Arena Dr, Davis, CA 95616
Phone
(916) 734-3772
(916) 734-7946 (Fax)
(916) 734-7946 (Fax)
Professional information
Kit Sang Lam, Sacramento CA
Specialties:
Internist
Address:
4501 X St, Sacramento, CA 95817
2700 Stockton Blvd, Sacramento, CA 95817
2700 Stockton Blvd, Sacramento, CA 95817
Education:
Stanford University, School of Medicine - Doctor of Medicine
University Medical Center - Fellowship - Hematology and Oncology (Internal Medicine)
University Medical Center - Residency - Internal Medicine
University Medical Center - Fellowship - Hematology and Oncology (Internal Medicine)
University Medical Center - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
Dr. Kit S Lam - MD (Doctor of Medicine)
Hospitals:
2700 Stockton Blvd, Sacramento 95817
CANCER CENTER-BONE MARROW
4501 X St, Sacramento 95817
The University of Arizona Medical Center
1501 North Campbell Ave, Tucson 85724
UC Davis Medical Center
2315 Stockton Blvd, Sacramento 95817
2700 Stockton Blvd, Sacramento 95817
CANCER CENTER-BONE MARROW
4501 X St, Sacramento 95817
The University of Arizona Medical Center
1501 North Campbell Ave, Tucson 85724
UC Davis Medical Center
2315 Stockton Blvd, Sacramento 95817
CANCER CENTER-BONE MARROW
4501 X St, Sacramento 95817
The University of Arizona Medical Center
1501 North Campbell Ave, Tucson 85724
UC Davis Medical Center
2315 Stockton Blvd, Sacramento 95817
2700 Stockton Blvd, Sacramento 95817
CANCER CENTER-BONE MARROW
4501 X St, Sacramento 95817
The University of Arizona Medical Center
1501 North Campbell Ave, Tucson 85724
UC Davis Medical Center
2315 Stockton Blvd, Sacramento 95817
Education:
Medical Schools
Stanford University
Graduated: 1984
Stanford University
Graduated: 1984
Aβ-Binding Small Molecules
US Patent:
8168800, May 1, 2012
Filed:
Oct 31, 2008
Appl. No.:
12/740329
Inventors:
Kit S. Lam - Davis CA, US
Ruiwu Liu - Sacramento CA, US
Hyun-Seok Hong - Davis CA, US
Izumi Maezawa - Davis CA, US
Ruiwu Liu - Sacramento CA, US
Hyun-Seok Hong - Davis CA, US
Izumi Maezawa - Davis CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C07D 491/052
US Classification:
5483021
Abstract:
In one aspect, the present invention provides for compounds and labeled compounds of Formula I, and pharmaceutical compositions thereof. In another aspect, the present invention provides for methods of using compounds or labeled compounds of Formula I for various therapeutic and imaging purposes, including, but not limited to, treating Alzheimer's disease in patient and imaging Aβ peptide aggregates in a patient.
Chemical Antibodies For Immunotherapy And Imaging
US Patent:
2010002, Jan 28, 2010
Filed:
Jun 28, 2007
Appl. No.:
12/306244
Inventors:
Kit S. Lam - Davis CA, US
Pappanaicken R. Kumaresan - Sacramento CA, US
Amanda Enstrom - Sacramento CA, US
Ruiwu Liu - Sacramento CA, US
Pappanaicken R. Kumaresan - Sacramento CA, US
Amanda Enstrom - Sacramento CA, US
Ruiwu Liu - Sacramento CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 51/00, A61K 49/00, A61K 39/395, C12Q 1/02, C12N 9/96, C07K 16/00
US Classification:
424 149, 424 91, 424 96, 4241781, 435 29, 435188, 5303911, 5303913, 5303915, 5303917, 5303919
Abstract:
The present invention provides antibody conjugates comprising a targeting agent covalently attached to an antibody or fragment thereof. The antibody conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue and for treating diseases and disorders such as cancer, inflammatory diseases, autoimmune diseases, infectious diseases, and neurological disorders. Kits containing the antibody conjugates described herein find utility in a wide range of applications including, for example, in vivo imaging and immunotherapy.
Nanocarriers For Drug Delivery
US Patent:
2011028, Nov 24, 2011
Filed:
Sep 22, 2009
Appl. No.:
13/120140
Inventors:
Kit S. Lam - Davis CA, US
Juntao Luo - Sacramento CA, US
Juntao Luo - Sacramento CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 51/12, A61K 9/14, A61K 31/337, A61P 35/00, A61K 31/704, A61K 31/7048, C07C 237/14, C07C 247/06, A61K 49/00, A61K 31/4745
US Classification:
424 129, 424 91, 424489, 514449, 514283, 514 34, 514 27, 564153, 552 12
Abstract:
The present invention provides a nanocarrier having an interior and an exterior, the nanocarrier comprising at least one conjugate, wherein each conjugate includes a polyethylene glycol (PEG) polymer. Each conjugate also includes at least two amphiphilic compounds having both a hydrophilic face and a hydrophobic face. In addition, each conjugate includes an oligomer, wherein at least 2 of the amphiphilic compounds are covalently attached to the oligomer which is covalently attached to the PEG. The nanocarrier is such that each conjugate self-assembles in an aqueous solvent to form the nanocarrier such that a hydrophobic pocket is formed in the interior of the nanocarrier by the orientation of the hydrophobic face of each amphiphilic compound towards each other, and wherein the PEG of each conjugate self-assembles on the exterior of the nanocarrier.
Heterocyclic Ligands For Integrin Imaging And Therapy
US Patent:
8486370, Jul 16, 2013
Filed:
Sep 7, 2007
Appl. No.:
12/440219
Inventors:
Richard D. Carpenter - Suisun City CA, US
Mirela Andrei - Ploiesti, RO
Ruiwu Liu - Sacramento CA, US
Kit S. Lam - Davis CA, US
Mark J. Kurth - Davis CA, US
Mirela Andrei - Ploiesti, RO
Ruiwu Liu - Sacramento CA, US
Kit S. Lam - Davis CA, US
Mark J. Kurth - Davis CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 51/00
US Classification:
424 169
Abstract:
The present invention provides αβintegrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unnatural amino acid or a D-amino acid, and wherein n is an integer of from 3 to 20. Methods are provided for administering the ligands for treating cancer, inflammatory diseases, and autoimmune diseases. Also provided are methods for administering the ligands for imaging a tumor, organ, or tissue in a subject.
Inhibitors Of Cyclin Kinase Inhibitor P21
US Patent:
2011030, Dec 8, 2011
Filed:
Sep 29, 2009
Appl. No.:
13/119152
Inventors:
Robert Weiss - Vacaville CA, US
Kit S. Lam - Davis CA, US
Ruiwu Liu - Sacramento CA, US
Kit S. Lam - Davis CA, US
Ruiwu Liu - Sacramento CA, US
Assignee:
The regents of the University of California - Oakland CA
International Classification:
A61K 31/454, C07D 235/18, C07D 403/06, A61P 35/00, C07D 401/04, A61K 31/4184, A61K 31/4375, C07D 401/06, C07D 455/02
US Classification:
514306, 546199, 5483097, 5483061, 546138, 514322, 514394
Abstract:
The present invention provides compounds that inhibit cyclin kinase inhibitor p21, such as compounds of formula I. The present invention also provides compositions including compounds of Formula I and a pharmaceutically acceptable excipient. In addition, the present invention provides methods of inhibiting cyclin kinase inhibitor p21 and of treating cancer.
Method For Screening Combinational Bead Library; Ligands For Cancer Cells
US Patent:
7262269, Aug 28, 2007
Filed:
Oct 8, 2003
Appl. No.:
10/682659
Inventors:
Kit S. Lam - Davis CA, US
Derick H. Lau - Gold River CA, US
Derick H. Lau - Gold River CA, US
Assignee:
The Regents of University of California - Oakland CA
International Classification:
C07K 5/00, C40B 30/04
US Classification:
530317, 530321, 530328
Abstract:
The invention includes a cell-growth-on-bead assay for screening a one-bead-one-compound combinatorial bead library to identify synthetic ligands for cell attachment and growth or proliferation of epithelial and non-epithelial cells. Cells are incubated with a compound bead library for 24 to 72-hours, allowing them to attach and grow on the beads. Those beads with cells growing are removed, and the ligand on the bead is identified. Also provided are ligands specific for cancer cells.
Preparation And Application Of Ligand-Biopolymer Conjugates
US Patent:
2004023, Nov 25, 2004
Filed:
Mar 31, 2004
Appl. No.:
10/815468
Inventors:
Kit Lam - Davis CA, US
Qingchai Xu - Dublin CA, US
Qingchai Xu - Dublin CA, US
Assignee:
Regent of the University of California - Oakland CA
International Classification:
C12Q001/68, G01N033/53, C12M001/34
US Classification:
435/006000, 435/007100, 435/287200
Abstract:
The present invention provides methods for the site-specific attachment of ligands to a biopolymer. These methods are suitable for microarray construction, biodegradable scaffold formation, cell or tissue growth, as well as the conjugates or products formed by those methods.
Bladder Cancer Specific Ligand Peptides
US Patent:
2012023, Sep 13, 2012
Filed:
Sep 23, 2010
Appl. No.:
13/497041
Inventors:
Hongyong Zhang - Davis CA, US
Kit S. Lam - Davis CA, US
Olulanu H. Aina - Elk Gove CA, US
Kit S. Lam - Davis CA, US
Olulanu H. Aina - Elk Gove CA, US
Assignee:
The Regents Of The University of California, Office of Technology - Oakland CA
International Classification:
A61K 39/395, C07K 7/06, C07K 19/00, A61P 35/00, G01N 21/64, G01N 21/76, G01N 27/72, A61K 38/03, C07K 4/00, G01N 33/53
US Classification:
4241341, 530300, 530329, 5303873, 435 71, 514 193
Abstract:
The present invention is directed to bladder cancer specific ligand peptides, comprising the amino acid sequence XDGRXGF (SEQ ID NO:1), and methods of their use, e.g., for imaging detection for diagnosis of bladder, tumor localization to guide transurethral resection of bladder cancer, imaging detection of bladder cancer for follow-up after the initial treatment that can replace or complement costly cystoscopy, imaging detection of metastatic bladder cancer, and targeted therapy for superficial and metastatic bladder cancer.